Literature DB >> 19839253

Bidirectional orbital approach enhances orbital abscess drainage.

E Eviatar, A Kessler, K Pitaro.   

Abstract

OBJECTIVES: Transnasal endoscopic management of subperiosteal orbital abscess (SPOA) secondary to acute rhinosinusitis has become very popular over the past two decades. We describe our transnasal endoscopic approach for orbital complications secondary to acute rhinosinusitis (SPOA and orbital abscess) and the efficacy criteria that can be used to ensure complete drainage.
METHODS: The charts of all patients who underwent surgery at Assaf Harofeh Medical Center between January 1993 and June 2007 were reviewed. Age, sex, clinical findings, antibiotic treatment, surgical procedure and outcome were recorded.
RESULTS: Nineteen patients with SPOA and three with orbital abscess underwent surgery during which wide exposure of the periorbita was performed. If the abscess was not identified, bidirectional orbital manipulation, while simultaneously keeping a seeker in the abscess space under endoscopic view, enhanced its identification and successful drainage. An immediate reduction in palpable orbital pressure was used as an efficacy criterion for adequate drainage.
CONCLUSION: The transnasal endoscopic approach for SPOA and orbital abscess can be enhanced by wide exposure of the periorbita and bidirectional orbital manipulation. Keeping track of orbital pressure during surgery by palpating the eye can be used as an efficacy criterion for assessing adequate drainage.

Entities:  

Mesh:

Year:  2009        PMID: 19839253     DOI: 10.4193/Rhin08.215

Source DB:  PubMed          Journal:  Rhinology        ISSN: 0300-0729            Impact factor:   3.681


  2 in total

Review 1.  Comprehensive review on endonasal endoscopic sinus surgery.

Authors:  Rainer K Weber; Werner Hosemann
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2015-12-22

2.  Management of superior subperiosteal orbital abscess.

Authors:  Haim Gavriel; Basel Jabrin; Ephraim Eviatar
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-02-21       Impact factor: 2.503

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.